Identify all M&A deals in your business sectors

Boston Scientific acquired Axonics for roughly $3.7bn, adding a fast-growing sacral neuromodulation and urology franchise built around a rechargeable implant for overactive bladder and incontinence, plus the Bulkamid urethral-bulking line. The deal hands Boston Scientific a direct challenger position to Medtronic in bladder- and bowel-control therapy, and fits the recurring-procedure, physician-driven profile it has favoured across its recent buy-and-build. Integration risk is contained — Axonics sells into urology and urogynecology channels that complement rather than overlap Boston Scientific's existing franchise.

The transaction was priced at $71.00 per share in cash — a modest premium reflecting Axonics' already-rich public valuation and its rapid share gains against Medtronic in sacral neuromodulation. For Boston Scientific the logic rests on growth rather than cost synergies: Axonics had been winning in a large, under-penetrated bladder- and bowel-control market, and pairing that momentum with Boston Scientific's global commercial reach should accelerate international expansion. The key watch items are regulatory clearance timing and retention of the specialist Axonics sales force, whose physician relationships anchor the franchise.